TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›PMN›Financials
Annual statements · SEC XBRL · FY2021 – FY2025

ProMIS Neurosciences Inc. (PMN) financials

Income statement

ProMIS Neurosciences Inc. (PMN) income statement, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Operating income-$8.29M-$23.4M-$14.3M-$16.8M-$40.2M
Net income-$9.79M-$18.1M-$13.2M$2.78M-$39.7M
EPS (diluted)-$1.69-$2.41-$1.07$2.63-$22.61

Cash flow

ProMIS Neurosciences Inc. (PMN) cash flow, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Operating cash flow-$9.31M-$17.0M-$10.8M-$27.2M-$28.1M
Capital expenditures$6.04K$1.98K———
Free cash flow-$9.31M-$17.0M———

Balance sheet

ProMIS Neurosciences Inc. (PMN) balance sheet, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Cash & equivalents$16.9M$5.88M$12.6M$13.3M$6.12M
Total assets$17.7M$6.92M$13.6M$18.9M$9.18M
Total liabilities$12.1M$8.27M$9.87M$2.42M$10.4M
Long-term debt$3.91M—$0.00——
Shareholders' equity$5.66M-$1.35M$3.75M$16.5M-$1.26M
Retained earnings-$62.2M-$80.3M-$93.5M-$90.7M-$130M
Shares (wtd avg diluted)5.79M7.50M12.3M1.06M1.76M

Every figure is extracted from ProMIS Neurosciences Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

Does PMN pay a dividend?
ProMIS Neurosciences Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full PMN analysis — verdict, score & filings →Is PMN a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.